► 1:21 Managing Challenging CML Cases CML Content Hub Susanne Saussele, MD, discusses #monitoring after #treatment #discontinuation in #CML.
► 2:08 Mitochondrial Metabolism Inhibitors as a CML Treatment? CML Content Hub @VignirHelgason, of @UofGlasgow, discusses #mitochondrial #metabolic #inhibitors for #CML.
► 1:41 Risk Stratifying CML Patients for Cardiovascular Adverse Events When Choosing First-Line Therapy CML Content Hub @mjmauroMD, of @MSKCancerCenter, discusses #risk stratification and #TKI selection in #CML.
► 1:53 5-Year Results Solidify Bosutinib’s Increased Efficacy vs Imatinib CML Content Hub @GCC_Cortes of @GACancerCenter discusses #bosutinib in #CML.
► 2:28 Optimizing CML Treatment: Latest Clinical Trial Data on TKI Efficacy and Dosage CML Content Hub @CoplandMhairi, of @UofGlasgow, discusses #TKI efficacy and #dosage.
► 13:25 An Overview of Research Program for Pompe Disease Pompe Disease Content Hub Priya Kishnani, MD, of @DukeMedSchool, discusses #translational #research on #PompeDisease.
► 1:37:47 Small Molecule Inhibitor Reduces Glycogen in Preclinical Mouse Models of Pompe Disease Pompe Disease Content Hub Julie Ullman, PhD, of @MazeInBiotech, discusses #preclinical #results on #MZE001 for #PompeDisease.
► 02:10 Multidisciplinary Approach to Managing Pompe Disease Pompe Disease Content Hub Priya Kishnani, MD, of @DukeMedSchool, discusses #multidisciplinary care for #PompeDisease.
► 54:32 Newborn Screening for Pompe Disease Pompe Disease Content Hub Damara Ortiz, MD, of @ChildrensPgh, discusses #screening for #PompeDisease.
► 1:31:53 CML Management and Emerging Therapies CML Content Hub Ehab Atallah, MD, of @MedicalCollege, and @mjmauroMD, of @MSKCancerCenter, discuss #emerging #therapies for #CML.